MAR001 for adults with high triglycerides and remnant cholesterol

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 mechanistic interventional trial comparing MAR001 with placebo to measure changes in postprandial triglycerides in adults who have elevated fasting triglycerides. Eligible participants must have two fasting triglyceride measurements at screening, an HbA1c between 5.7% and 8.5%, and stable diet and medication regimens. Key exclusions include acute or chronic liver disease, uncontrolled HIV, active viral hepatitis, type 1 diabetes, recent diabetic ketoacidosis, and use of diabetes medications other than metformin. The study is conducted at a single Marea Therapeutics site in Chula Vista, California, and focuses on laboratory measures of triglycerides and remnant cholesterol following a standardized challenge.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willingness to provide informed consent and comply with the intervention and all study assessments
* Two fasting TG collected at two separate, consecutive visits at least 7 days apart during the Screening period
* HbA1c ≥ 5.7% and ≤ 8.5%
* Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study
* Stable drug regimen (appropriate if relevant) prior to screening visit and no planned changes during screening or trial participation

Exclusion Criteria:

* Acute or chronic liver disease
* Diabetes medications (other than metformin)
* History of type 1 diabetes mellitus or history of diabetic ketoacidosis
* Newly diagnosed T2DM
* Participants with known active hepatitis A, B, or C
* Participants who are known to have uncontrolled human immunodeficiency virus (HIV) infection
* Uncontrolled hypothyroidism
* Any condition that prevents the participant from complying with study procedures

Where it's running

• Marea Site 301
  Chula Vista, California, United States Recruiting

Study contacts

• Study coordinator: Andrew Lane
• Email: MAR-104-info@mareatx.com
• Phone: 415-766-3610

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ion775 for high triglyceride levels: safety, tolerability, and how well it works

  A drug called ION775 is being tested to see if it can safely lower fasting triglycerides in adults with hypertriglyceridemia or severe hypertriglyceridemia who are already on standard lipid medicines.

  Recruiting at 17 sites Phase 2 Ionis Pharmaceuticals, Inc. · Lincoln, California and 17 other locations · NCT07604974

• Russian registry for people with very high triglycerides

  This registry collects health and genetic information from people in Russia who have very high triglycerides (≥10 mmol/L) to see what their causes, care, and outcomes look like.

  Recruiting at 6 sites Russian Cardiology Research and Production Center · Astrakhan and 5 other locations · NCT07508930

• CTX310 for refractory high triglycerides or LDL cholesterol

  This trial will test whether a single IV dose of CTX310 is safe and tolerated in adults whose high triglycerides or LDL cholesterol have not responded to available treatments.

  Recruiting at 16 sites Phase 1 CRISPR Therapeutics · Hialeah, Florida and 16 other locations · NCT07491172

• High-speed centrifugation to enable anti-Xa testing on lipemic (fatty) blood samples

  This will test whether spinning fatty (lipemic) blood samples very fast helps the lab get accurate anti-Xa measurements for adults on anti-Xa anticoagulant medications.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07200674

• JMT202 injections for adults with high triglycerides

  This will test whether repeated subcutaneous injections of JMT202 are safe and well tolerated in Chinese adults with high triglyceride levels.

  Recruiting Phase 1/2 Shanghai JMT-Bio Inc. · Beijing, Beijing Municipality · NCT07140809

• MAR001 in adults with high triglycerides and remnant cholesterol

  This study tests MAR001 against placebo to see if it lowers triglycerides and remnant cholesterol in adults with elevated levels.

  Recruiting at 21 sites Phase 2 Marea Therapeutics · Anniston, Alabama and 54 other locations · NCT07028749

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.